All Stories

  1. Pesticide exposure associated with mild cognitive impairment & depression among agricultural workers: Case control study in rural India
  2. Subset estimators for spherical mean: effect of contamination and exact algorithm for computation
  3. Diamond Sign in Calpainopathy
  4. Global, regional, and national burden of headache disorders, 1990–2021, with forecasts to 2050: A Global Burden of Disease study 2021
  5. Relative efficiency of higher order norm-based estimator over the least squares estimator
  6. Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019
  7. Partial sequential testing for comparing two univariate normal distributions
  8. Motor and Non-motor Neurologic Symptoms of Wilson’s Disease: Exploring the Associations
  9. Success of anti-amyloid therapy answers few but raises many questions
  10. Progressive Supranuclear Palsy in India: Past, Present, and Future
  11. Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  12. Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021
  13. Exome sequencing identifiesABCA7as an important gene for familial AD cases from Eastern India
  14. Mental health problems raise the odds of cognitive impairment in COVID-19 survivors
  15. Fixed accuracy confidence intervals for variance under first-order stationary autoregressive processes
  16. An Effort to Identify Genetic Determinants in Siblings With Wilson Disease Manifesting Striking Clinical Heterogeneity: An Exome Profiling Study of Two Indian Families
  17. Incorporating treatment-covariate interaction in designing a covariate adjusted response adaptive allocation for binary response trials
  18. Sequential Estimation of Conditional Odds Ratio
  19. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  20. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  21. Fixed width confidence interval estimation for general continuous responses under a response adaptive design
  22. Global Health Trends 1950–2021: Impact of COVID-19 on Mortality and Population Growth
  23. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  24. Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
  25. Analysis of Semiology, Lesion Topography and Treatment Outcomes: A Prospective Study on Post Thalamic Stroke Holmes Tremor
  26. Illiterate Addenbrooke’s Cognitive Examination-III in Three Indian Languages: An Adaptation and Validation Study
  27. Reply to Kljajevic's “Increasing sensitivity of clinical proverb tests for diagnosis of dementia”
  28. Post-Infective Rhombencephalitis with Bilateral Olivary Hypertrophic Degeneration
  29. Fixed-width confidence interval of log odds ratio in correlated setup for crossover design
  30. Unfurling a case of encephalitis with Acanthamoeba after a near-drowning event
  31. A rare case of Uner-Tan syndrome with incidentally detected choroid plexus papilloma
  32. An alternative procedure for testing equality of treatment effects under circular responses
  33. The Genetic Drivers of Juvenile, Young, and Early‐Onset Parkinson's Disease in India
  34. Genetic Variations and Altered Blood mRNA Level of Circadian Genes and BDNF as Risk Factors of Post-Stroke Cognitive Impairment Among Eastern Indians
  35. Arg4810Lys mutation in RNF213 among Eastern Indian non-MMD ischemic stroke patients: a genotype–phenotype correlation
  36. Sample sizes required to estimate the protective efficacy of a vaccine when there is an unequal allocation of individuals across the vaccine and placebo groups
  37. The scope of using pragmatic language tests for early detection of dementia: A systematic review of investigations using figurative language
  38. Genetic Variations and Altered Blood mRNA Level of Circadian Genes and BDNF as Risk Factors of Post-Stroke Cognitive Impairment among Eastern Indians
  39. Evaluation ofApolipoprotein e4allele as susceptible factor for neurodegenerative diseases among Eastern Indians
  40. The genetic drivers of juvenile, young, and early-onset Parkinson’s Disease in India
  41. South Asian medical cohorts reveal strong founder effects and high rates of homozygosity
  42. Arg4810Lys Mutation in RNF213 among Eastern Indian Non-MMD Ischemic Stroke Patients: A Genotype-Phenotype Correlation
  43. Limb to Cranial Overflow Dystonia in a Patient After Stroke
  44. An Indian Young-onset Dementia With Parkinsonism With Double Heterozygous Mutations in ABCA7 and PRKN Identified Through Whole-exome Sequencing
  45. Gastrointestinal, Respiratory, and Olfactory Neurotropism Of Sars-Cov2 as a Possible Trigger of Parkinson’s Disease
  46. Brain-enriched miR-128: Reduced in exosomes from Parkinson’s patient plasma, improves synaptic integrity, and prevents 6-OHDA mediated neuronal apoptosis
  47. Charcot Arthropathy of Elbow Joint in Syringomyelia
  48. Cognitive Stimulation Therapy as an Adjunctive Treatment for Mild to Moderate Dementia
  49. Melatonin in Combination with Pramipexole Treatment Can Reduce the Progression of Rotenone-Induced Parkinsonism in Rats
  50. A study of the impact of policy interventions on daily COVID scenario in India using interrupted time series analysis
  51. Prior effective sample size in phase II clinical trials with mixed binary and continuous responses
  52. Multi-arm covariate adjusted response adaptive designs for ordinal outcome clinical trials
  53. Adrenocorticotropic Hormone-Induced Dyskinesia and Probable Sudden Unexpected Death in an Infant with Early Infantile Developmental and Epileptic Encephalopathy—Infantile Epileptic Spasm Syndrome Overlap
  54. Pragmatic deficits in patients with schizophrenia and right hemisphere damage: A pilot study
  55. Exosome-derived miR-128 is decreased in Parkinson’s patient plasma that maintains synaptic integrity and protects against both intrinsic and extrinsic pathways of neuronal apoptosis in models of Parkinson’s disease
  56. Genome‐Wide Polygenic Score Predicts Large Number of High Risk Individuals in Monogenic Undiagnosed Young Onset Parkinson's Disease Patients from India
  57. Adaptation and Validation of Addenbrooke’s Cognitive Examination-III in Bengali for Screening MCI and Dementia
  58. Health status of persons with dementia and caregivers’ burden during the second wave of COVID-19 pandemic: an Indian study
  59. Cognitive Profile of Large-Vessel Vascular Dementia—An Observational Study from a Tertiary Care Center in Kolkata
  60. Trimmed estimator for circular–circular regression: breakdown properties and an exact algorithm for computation
  61. Sequential confidence interval for comparing two Bernoulli distributions in a non-conventional set-up
  62. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
  63. Exploring caregiver burden and health condition of dementia patients during lockdown due to COVID-19 pandemic
  64. Parakinesia Brachialis Oscitans – a Rare Post-Stroke Phenomenon
  65. Gait Apraxia with Exaggerated Upper Limb Movements as Presentation of AARS2 Related Leukoencephalopathy
  66. An online survey on stress, anxiety, and depression in terminal batch students of 2020 during lockdown due to COVID-19 pandemic
  67. CSF P-tau 231 as biomarker in alzheimer's disease
  68. Comparative Study of Risk Factors and Cognitive Profile of Small- and Large-Vessel Vascular Dementia – A Clinic Based Study
  69. Evaluation of non-motor symptoms in wilson disease using the parkinson's disease nonmotor symptoms questionnaire: A pilot cross-sectional study and critical assessment
  70. Regression Models for Directional Variables
  71. Correlation of ATP7B gene mutations with clinical phenotype and radiological features in Indian Wilson disease patients
  72. ApoE ε4 and IL-6-174G/C Polymorphism may Lead to Early Onset of Alzheimer's Disease with Atypical Presentation
  73. An optimal response adaptive design for multi-treatment clinical trials with ordinal categorical outcomes
  74. Use of multidimensional item response theory methods for dementia prevalence prediction: an example using the Health and Retirement Survey and the Aging, Demographics, and Memory Study
  75. The burden of neurological disorders across the states of India: the Global Burden of Disease Study 1990–2019
  76. Perception about Etiology of Epilepsy and Help-Seeking Behavior in Patients with Epilepsy
  77. Behavioral variations among vascular cognitive impairment subtypes – A comparative study
  78. A comparison of cognitive performances between neuromyelitis optica spectrum disorder and multiple sclerosis patients in Indian context
  79. Change‐point analysis through integer‐valued autoregressive process with application to some COVID‐19 data
  80. COVID-19 and central nervous system interplay: A big picture beyond clinical manifestation
  81. Anti-MOG antibody associated long segment myelitis presenting as anterior cord syndrome
  82. Ataxia and Myoclonus with a Cherry-Red Spot Unfurling an Unusual Phenotypic Presentation of Sialidosis Type 1
  83. Fixed-width confidence interval for treatment difference in multinomial sampling
  84. Identification of GBA mutations among neurodegenerative disease patients from eastern India
  85. Clinical Study of 668 Indian Subjects with Juvenile, Young, and Early Onset Parkinson’s Disease
  86. A study of Mutation in ATP7B gene and its correlation with clinical phenotype and radiological features in Wilson Disease patients
  87. Predicting Long‐Term Outcome of Patients of Early Parkinsonism with Acute Levodopa Challenge Test
  88. Spectrum of Anti-NMDA Receptor Antibody Encephalitis: Clinical Profile, Management and Outcomes
  89. Effect of COVID-19 related lockdown on nonmotor symptoms of Parkinson's Disease
  90. Non-motor features of amyotrophic lateral sclerosis: A clinic-based study
  91. Global mortality from dementia: Application of a new method and results from the Global Burden of Disease Study 2019
  92. The Burden of Dementia due to Down Syndrome, Parkinson’s Disease, Stroke, and Traumatic Brain Injury: A Systematic Analysis for the Global Burden of Disease Study 2019
  93. Burden of nonmotor symptoms in Parkinson’s disease patients from eastern India
  94. An Optimal Response-Adaptive Design for Multi-treatment Clinical Trials with Circular Responses
  95. A nonparametric two‐sample test using a generalφ‐divergence‐based mutual information
  96. Mapping routine measles vaccination in low- and middle-income countries
  97. A Comparative Study of the Behavioral Profile of the Behavioral Variant of Frontotemporal Dementia and Parkinson’s Disease Dementia
  98. Difference of PCA from typical AD and amnestic MCI
  99. Charcot-Marie-Tooth disease type 4J with spastic quadriplegia, epilepsy and global developmental delay: a tale of three siblings
  100. Rabbit syndrome in anti-NMDAR antibody encephalitis: a unique association
  101. Orientation relationship in finite dimensional space
  102. Subnational mapping of under-5 and neonatal mortality trends in India: the Global Burden of Disease Study 2000–17
  103. Adaptive two-treatment three-period crossover design for normal responses
  104. Spectrum of anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-associated diseases: an Indian perspective
  105. Discussion on “Predictively consistent prior effective sample sizes,” by Beat Neuenschwander, Sebastian Weber, Heinz Schmidli, and Anthony O'Hagan
  106. “Clinical profile of genetically proven huntington's disease patients from eastern india”
  107. Role of LRRK2 variant p.Gly2019Ser in patients with Parkinsonism
  108. Multi-arm response-adaptive designs for circular responses
  109. Odds ratio based two-stage group sequential analysis for two-treatment two-period crossover trials
  110. Young-onset sporadic Creutzfeldt–Jakob disease with atypical phenotypic features: a case report
  111. Serum 24‐hydroxycholesterol in probable Alzheimer's dementia: Reexploring the significance of a tentative Alzheimer's disease biomarker
  112. A multi-treatment response adaptive design for ordinal categorical responses
  113. Cochran–Mantel–Haenszel test with bivariate binomial model on surrogate marker analysis
  114. A response adaptive design for ordinal categorical responses weighing the cumulative odds ratios
  115. Wilson's disease: a cognitive neuropsychological perspective
  116. OLS: Is That So Useless for Regression with Categorical Data?
  117. In Unexplained Altered Sensorium - Look for Arterial Ammonia Level
  118. A study on short term outcome of stroke in a rural tertiary care center of Sub Himalayan Terai
  119. A class of Covariate-Adjusted Response-Adaptive Allocation Designs for Multitreatment Binary Response Trials
  120. A response adaptive design for ordinal categorical responses
  121. Time series analysis of categorical data using auto-odds ratio function
  122. Distribution and time‐series modelling of ordinal circular data
  123. Epidemiology of Parkinson’s Disease
  124. Modelling of low count heavy tailed time series data consisting large number of zeros and ones
  125. Behavioural and Psychological Symptoms of Dementia: Correlates and Impact on Caregiver Distress
  126. Rare Intronic Variations in TP73 Gene Found in Patients with Alzheimer’s Disease
  127. Circular‐circular regression model with a spike at zero
  128. Optimal response and covariate-adaptive biased-coin designs for clinical trials with continuous multivariate or longitudinal responses
  129. Fixed-width confidence interval of log odds ratio for joint binomial and inverse binomial sampling
  130. An adaptive allocation design for circular treatment outcome
  131. Multiple circular–circular regression
  132. Wavelet-based Bayesian nonlinear regression for the air pollution effects on clinic visits in small areas of Taiwan
  133. Fixed-width confidence interval for covariate-adjusted response-adaptive designs
  134. Role of Pro-Inflammatory Cytokines and Vitamin D in Probable Alzheimer's Disease with Depression
  135. Reply #2 to: Glycemic Choreoballism
  136. Comparison of treatments in a cataract surgery with circular response
  137. On a class of optimal covariate-adjusted response adaptive designs for survival outcomes
  138. A covariate-adjusted response-adaptive allocation for a general class of continuous responses
  139. Irreversible Hemichorea–Hemiballism in a Case of Nonketotic Hyperglycemia Presenting as the Initial Manifestation of Diabetes Mellitus
  140. ROLE OF VITAMIN D SIGNALING IN SPORADIC ALZHEIMER’S DISEASE: A CLINICO-EXPERIMENTAL STUDY
  141. Epidemiology of dementia and its burden in the city of Kolkata, India
  142. Development of Bengali Audio–Visual Test Battery for Assessment of Pragmatic Skills: Preliminary Normative Data Based on Educational Level
  143. True endpoint reduction by surrogate endpoints
  144. Bayesian Forecasting for Time Series of Categorical Data
  145. Bayesian optimal response-adaptive design for binary responses using stopping rule
  146. Odds ratio-based group sequential analysis for joint binomial and inverse binomial sampling
  147. Inferences in median regression models for asymmetric longitudinal data: A quasi-likelihood approach
  148. Modelling circular random variables with a spike at zero
  149. Study of visuospatial skill in patients with dementia
  150. Spinocerebellar ataxia type 6 in eastern India: Some new observations
  151. Gut dysfunction in Parkinson's disease
  152. Cognitive impairment in idiopathic Parkinson's disease
  153. Alzheimer and Parkinson’s Disease -Two Faces of the Same Disease?
  154. Sporadic and familial myoclonic dystonia: Report of three cases and review of literature
  155. Fixed-width confidence interval for two-stage response-adaptive designs in ridit analysis
  156. Coherent forecasting for count time series using Box–Jenkins's AR(p) model
  157. Coherent forecasting for over-dispersed time series of count data
  158. Count Distribution for Generalized Weibull Duration with Applications
  159. Time Series of Zero-Inflated Counts and their Coherent Forecasting
  160. Modeling time series of counts with a new class of INAR(1) model
  161. Epilepsy patients with malformations of cortical development: Experience from a tertiary care centre in Eastern India
  162. Sequential and Two-Stage Fixed-Width Confidence Interval Estimation in Response-Adaptive Designs
  163. Genetic and clinical profile of patients of Duchenne muscular dystrophy: Experience from a tertiary care center in Eastern India
  164. Nonparametric Estimation of Maximum Tolerated Dose (MTD) In The Context of Phase I Clinical Trials
  165. Reactive Oxygen Species, Redox Signaling and Neuroinflammation in Alzheimer's Disease: The NF-κB Connection
  166. Coherent forecasting for stationary time series of discrete data
  167. Retrobulbar optic neuropathy secondary to isolated sphenoid sinus disease
  168. Author′s response on "Neuropsychiatric profiles in patients with Alzheimer′s disease and vascular dementia"
  169. Therapy of NMO spectrum disorders
  170. Bangur Institute of Neurosciences: One of the premier neurology/neurosurgery teaching institutes of the country
  171. Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment
  172. Linear increment in efficiency with the inclusion of surrogate endpoint
  173. Modelling and coherent forecasting of zero-inflated count time series
  174. Altered Serum Levels of Adipokines and Insulin in Probable Alzheimer's Disease
  175. Response-Adaptive Allocation for Circular Data
  176. Raised Serum Proinflammatory Cytokines in Alzheimer's Disease with Depression
  177. Independent component analysis and clustering for pollution data
  178. Air pollution effects on clinic visits in small areas of Taiwan revisited
  179. Odds Ratio for 2 × 2 Tables: Mantel–Haenszel Estimator, Profile Likelihood, and Presence of Surrogate Responses
  180. Auto-association measures for stationary time series of categorical data
  181. Shift-invariant target in allocation problems
  182. Unbalanced and Partial Group Sequential Methods for Normal Responses in Clinical Trials
  183. Clinical features, MRI brain, and MRS abnormalities of drug-naοve neurologic Wilson′s disease
  184. Clinical profile and genetic correlation of patients with spinocerebellar ataxia: A study from a tertiary care centre in Eastern India
  185. Neuropsychiatric profiles in patients with Alzheimer′s disease and vascular dementia
  186. Adrenomyeloneuropathy with bulbar palsy: A rare association
  187. Randomised Response-Adaptive Designs in Clinical Trials
  188. Optimal target allocation proportion for correlated binary responses in a
  189. Visual Manifestations in Alzheimer’s disease
  190. Genetic study on frontotemporal lobar degeneration in India
  191. Compound designs for dose‐finding in the presence of nondesignable covariates
  192. Case series of probable sporadic Creutzfeldt-Jakob disease from Eastern India
  193. Statistical analysis of discrete-valued time series using categorical ARMA models
  194. Near efficient target allocations in response-adaptive randomization
  195. On closeness of the Mantel–Haenszel estimator and the profile likelihood based estimator of the common odds ratio from multiple tables
  196. A response-adaptive design in crossover trial
  197. Associations between Pollen Counts, Pollutants, and Asthma-Related Hospital Admissions in a High-Density Indian Metropolis
  198. Response-adaptive designs for continuous treatment responses in phase III clinical trials: A review
  199. Seizure, spinal schwannoma, peripheral neuropathy and pulmonary stenosis - A rare combination in a patient of Neurofibromatosis 1
  200. Some inferential procedures in randomized repeated measurement design for binary response
  201. Optimal response-adaptive allocation designs in phase III clinical trials: Incorporating ethics in optimality
  202. A new response-adaptive design for continuous treatment responses for phase III clinical trials
  203. Multi-treatment optimal response-adaptive designs for phase III clinical trials
  204. Distribution of Odds Ratio in 2 × 2 Contingency Table: Adjustment for Correlation
  205. Covariate-adjusted response-adaptive designs for longitudinal treatment responses: PEMF trial revisited
  206. Estimating treatment difference for binary responses in the presence of surrogate endpoints
  207. Availability of a one-unit system supported by several spares and repair facilities
  208. Descriptive measures for nominal categorical variables
  209. Asthma‐related hospital admissions in an Indian megacity: role of ambient aeroallergens and inorganic pollutants
  210. A covariate‐adjusted adaptive design for two‐stage clinical trials with survival data
  211. An optimal response-adaptive design with dual constraints
  212. Reduction of Variability of Response-Adaptive Designs for Continuous Treatment Responses in Phase 3 Clinical Trials
  213. A general adaptive allocation design for continuous responses in the presence of covariates
  214. A Bayesian adaptive design for two-stage clinical trials with survival data
  215. Discrete-valued ARMA processes
  216. Measures of association for nominal categorical variables
  217. Time series analysis of categorical data using auto-mutual information
  218. Kernel-Based Response-Adaptive Design for Continuous Responses
  219. An Urn Model for Odds-Ratio-Based Response-Adaptive Phase III Clinical Trials for Two or More Treatments
  220. Bayesian Nonlinear Regression for the Air Pollution Effects on Daily Clinic Visits in Small Areas of Taiwan
  221. Time series analysis of hybrid neurophysiological data and application of mutual information
  222. Intermediate Monitoring, Sample Size Reassessment, and Multi-Treatment Optimal Response-Adaptive Designs for Phase III Clinical Trials with More Than One Constraint
  223. Optimal Response‐Adaptive Designs for Normal Responses
  224. Discussion on “A Hybrid Selection and Testing Procedure with Curtailment for Comparative Clinical Trials” by Elena M. Buzaianu and Pinyuen Chen
  225. Chapter-14 Dementia in Parkinson�s Disease
  226. Neurological disorders in children and adolescents
  227. Bivariate versus univariate ordinal categorical data with reference to an ophthalmologic study
  228. Drop-the-loser design in the presence of covariates
  229. Controlling Type-I Error Rate in Monitoring Structural Changes Using Partially Sequential Procedures
  230. Discussion on “Second-Guessing Clinical Trial Designs” by Jonathan J. Shuster and Myron N. Chang
  231. Dysarthric Bengali speech: A neurolinguistic study
  232. Maximum trimmed likelihood estimator for multivariate mixed continuous and categorical data
  233. Odds ratio for a single 2 × 2 table with correlated binomials for two margins
  234. Optimal Failure-Success Response-Adaptive Designs for Binary Responses
  235. Community survey of primary dystonia in the city of Kolkata, India
  236. Adaptive two-treatment two-period crossover design for binary treatment responses incorporating carry-over effects
  237. Adaptive two‐treatment two‐period crossover design for binary treatment responses
  238. An epidemiologic study of mild cognitive impairment in Kolkata, India
  239. Optimal Response‐Adaptive Designs for Continuous Responses in Phase III Trials
  240. Statistical Advances in the Biomedical Sciences
  241. A covariate adjusted two‐stage allocation design for binary responses in randomized clinical trials
  242. A Prospective Community-Based Study of Stroke in Kolkata, India
  243. Testing for the Absence of Random Effects in a Two-way Nested Design with Mixed Effects Model: A Nonparametric Approach
  244. Response-adaptive designs for continuous outcomes
  245. Covariate-Adjusted Adaptive Designs for Continuous Responses in a Phase III Clinical Trial: Recommendation for Practice
  246. Hypotheses on the Effect of Cadmium on Glutathione Content of Red Blood Corpuscles
  247. Marginal Regression for Binary Longitudinal Data in Adaptive Clinical Trials
  248. Bayesian Adaptive Biased‐Coin Designs for Clinical Trials with Normal Responses
  249. 0704 Prevalence of mild cognitive impairment — A population based study in the city of Kolkata
  250. Adaptive biased-coin designs for skewing the allocation proportion in clinical trials with normal responses
  251. A RANDOMIZED LONGITUDINAL PLAY‐THE‐WINNER DESIGN FOR REPEATED BINARY DATA
  252. Inference for a RPW‐Type Clinical Trial with Repeated Monitoring for the Treatment of Rheumatoid Arthritis
  253. Scheduling optimal examination times in a simple illness–death model
  254. Generating correlated ordinal categorical random samples
  255. Missing responses in adaptive allocation design
  256. An adaptive allocation for continuous response using Wilcoxon–Mann–Whitney score
  257. Randomized allocation procedure for testing a normal mean with known variance
  258. A Bayesian analysis of the 4‐year follow‐up data of the Wisconsin epidemiologic study of diabetic retinopathy
  259. Incorporating Inter‐item Correlations in Item Response Data Analysis
  260. Availability of a periodically inspected system, maintained under an imperfect-repair policy
  261. Non‐parametric group sequential designs in randomized clinical trials
  262. A new formulation of stress–strength reliability in a regression setup
  263. Interval Estimation in Adaptive Allocations Using Point Estimates
  264. A Bayesian analysis of zero-inflated generalized Poisson model
  265. Generalized Delayed Response in Randomized Play-the-Winner Rule
  266. A Bayesian adaptive design in clinical trials for continuous responses
  267. A new bivariate binomial distribution
  268. Test of Bernoulli success probability in inverse sampling for nearer alternatives using adaptive allocation
  269. An efficient design for model discrimination and parameter estimation in linear models
  270. Optimal Choice of Design Parameter in an Adaptive Design
  271. A Bayesian analysis of bivariate ordinal data: Wisconsin epidemiologic study of diabetic retinopathy revisited
  272. Adaptive designs for binary treatment responses in phase III clinical trials: controversies and progress
  273. Adaptive designs for normal responses with prognostic factors
  274. An optimal design for simple illness–death model
  275. Availability of a system maintained through several imperfect repairs before a replacement or a perfect repair
  276. Comparison of two treatments with heterogeneous experimental units
  277. Bayesian Analysis of Clustered Regression Models for Mixed Discrete and Continuous Outcomes – An Application to Depressive Disorder Data
  278. Sequential nonparametric tests based on randomized play-the-winner rule for restricted bivariate alternatives
  279. Sequential-type nonparametric test using Mann-Whitney statistics
  280. Delayed response in randomized play-the-winner rule revisited
  281. Comparison of Two Treatments Under Delayed Response
  282. Some Sequential Tests in Clinical Trials Based on Randomized-Play-The-Winner Rule
  283. Delayed Response in Randomized Play-The-Winner Rule; A Decision Theoretic Outlook
  284. Some Nonparametric Group Sequential-Type Tests for Two Population Problems